A meta-analysis of 38 studies and 14,745 subjects evaluated serum HE4 as a diagnostic biomarker for ovarian cancer, showing promising discriminative power with acceptable sensitivity (0.79) and clinically meaningful specificity (0.92). This evidence concerns the gene WFDC2 and ovarian cancer.